ADVERTISEMENT
Psychedelics Briefs: Awakn Life Sciences, Numinus Wellness, Revitalist, Wake Network
Awakn Life Sciences Partners With Catalent
Awakn Life Sciences, a therapeutics developer with a near-term focus on treating alcohol use disorder, announced this week that it has signed a drug development agreement with Catalent to optimize development, launch, and supply of patient treatments across multiple modalities.
Through their partnership, the companies will focus on investigating a market-ready, proprietary formulation and optimized delivery route for MDMA using Catalent’s orally disintegrating tablet technology known as Zydis. Awakn said in a news release announcing the deal that it plans to use the Zydis technology in its late-stage MDMA-assisted therapy clinical trials.
Through its partnership with Catalent, Awakn will be able to conduct feasibility studies for treatments to address addiction, including substance and behavioral addictions, as well as anxiety, depression, post-traumatic stress disorder (PTSD), eating disorders, and other mental health conditions.
Numinus Reports Active Quarter Following Acquisition
Numinus Wellness announced that following its acquisition of Novamind, which was completed on June 10, the company has seen growth across multiple sectors in its latest fiscal quarter. During the month of August, Numinus held 6200 client appointments across its wellness clinics in the US and Canada, a 25% month-over-month increase. Of the appointments held in the company’s US clinics in August, 15% were with new clients.
Ketamine therapy sessions were up by 35%, and transcranial magnetic stimulation appointments increased by 23%.
Meanwhile, Cedar Clinical Research, the Numinus clinical trial management trial division acquired through Novamind, recruited 178 clinical trial participants for 16 third-party studies in the quarter, a 19% increase in clinical trial participation over the prior 3 months.
Revitalist, Wake Network Partner on Psilocybin Retreat for Vets
Revitalist Lifestyle and Wellness announced on Tuesday that it has entered into a partnership with Wake Network to jointly offer ketamine infusions in the United States and psilocybin clinical retreats internationally with a focus on veterans’ needs.
“UNIT Retreat,” an 8-day program, will be held October 10-17, with 3 days at the Veteran’s Healing Farm in Hendersonville, North Carolina, followed by a 5-day psilocybin retreat in Jamaica. The program will incorporate yoga, meditation, hiking, sound therapy, and elective psilocybin therapy to treat depression, anxiety, and post-traumatic stress.
In a news release announcing the program, Revitalist said it aims to provide additional retreats monthly after the inaugural edition in October.
Revitalist operates a network of 9 clinics in 6 states, offering access to psychedelic medicine, vitamin infusions, and other lifestyle optimization services. Wake Network is a psilocybin bioscience company focused on advancing the field of psychedelic and fungi-based therapeutics to address the need for mental health support in medicine. Wake currently is producing psilocybin and medicinal mushroom products through pharmaceutical-grade research.
References
